Monte Rosa Therapeutics : DDW 2024 – MRT 6160, a VAV1 Directed Molecular Glue Degrader, Inhibits Disease Progression in a T cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin Expression

#Tu1727: MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a T-cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin...

Related Keywords

United States ,Boston ,Massachusetts ,Switzerland ,John Castle ,Sharon Townson ,Markus Warmuth ,Elisa Liardo ,Xudong Wang ,Shailee Vora ,Laura Mcallister ,Mary Zlotosch ,Daniel Lam ,Eswar Krishnan ,Bowen Wallace ,Chris King ,Alison Paterson ,Filip Janku ,Bradley Demarco ,Sophia Nguyen ,Peter Trenh ,Xavi Lucas ,Debora Bonenfant ,Ilaria Lamberto ,Marisa Peluso ,Foram Desai ,Adamnr Cartwright ,Lucas Gyger , ,Nanostring Autoimmune Profiling Panel ,Monte Rosa Therapeutics Inc ,Directed Molecular Glue Degrader ,Inhibits Disease Progression ,Reduced Calprotectin Expression ,Katie May ,Daric Wible ,Steven De Beukelaer ,Rosa Therapeutics Inc ,Rosa Therapeutics ,Future Development ,Monte Rosa ,